7results about How to "Increased activation" patented technology

The present invention relates to a specific binding protein targeting PD-L1 and CD73, wherein the specific binding protein is capable of specifically binding to PD-L1 and / or a fragment thereof, and CD73 and / or a fragment thereof. The present invention further relates to use of the specific binding protein in the treatment, prevention and / or diagnosis of diseases such as immune diseases, acute and chronic inflammatory diseases, and tumor diseases.

The present invention relates to 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compounds of general formula (i), wherein x, r1, r2, r3, r4, and r5 are as defined in the description. The invention also relates to methods for preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular cancer or diseases with dysregulation of immune responses or other disorders associated with aberrant AHR signals, as monotherapy or in combination with other active ingredients.

This invention provides a perovskite solar cell and its fabrication method. The fabrication method of the perovskite solar cell includes the following steps: forming a first electrode layer on one side surface of a substrate; and forming NiO on one side surface of the first electrode layer using a magnetron sputtering process. x The layer uses a nickel oxide target. During magnetron sputtering, oxygen is introduced into the magnetron sputtering chamber at a flow rate of 4.5 sccm to 15 sccm and a temperature of 100°C to 140°C. The aforementioned NiO... x The layer preparation method facilitates the doping of oxygen molecules into the nickel oxide film, thus achieving the desired oxygen doping level without the need for excessive oxygen introduction, and enabling precise control of NiO. x The oxygen content of the layer; the low oxygen content in the magnetron sputtering chamber can prevent NiO. x Excessive oxygen doping in the NiO layer ensures the photoelectric conversion efficiency of the perovskite solar cell; the aforementioned NiO x The layer preparation method also improves the uniformity of oxygen distribution within the magnetron sputtering chamber, thereby enhancing the NiO content. x The uniformity of oxygen doping in the layer improves the performance uniformity of perovskite solar cells.

The invention relates to the field of antibodies useful in therapeutic and diagnostic applications targeting cd127, the alpha chain of the il7 receptor, and in particular provides humanized monoclonal antibodies against cd127, especially human cd127, their therapeutic uses and diagnostic applications.

The invention discloses a culture method of DC-CTL cells, and particularly relates to the technical field of biotechnology and medicine. The invention provides a novel DC-CTL cell culture method based on iPSC, aiming at the technical problems that a traditional DC-CTL cell culture method is limited in cell source, greatly influenced by individual difference, poor in stability and repeatability, insufficient in cell activity and killing ability and the like. A self-made additive and a specific cell factor are combined, SOCS1-siRNA is transfected through a liposome transfection method, the SOCS1 gene is effectively silenced, and the T cell activity is enhanced. According to the method, the proportion of CD3 + CD8 + T cells in the DC-CTL cells reaches 85% or above, the content of IFN-gamma is larger than or equal to 500 pg / mL, the content of TNF-alpha is larger than or equal to 300 pg / mL, and the killing rates under the effect target ratios of 10: 1, 20: 1 and 40: 1 reach 57%, 63% and 72% respectively.

The invention provides methods and compositions for treating locally advanced or metastatic breast cancer and for enhancing immune function in an individual having locally advanced or metastatic breast cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane.

The utility model discloses an automatic stirrer for activating saccharomyces cerevisiae, which comprises a supporting seat, an anti-caking component, a mixing component, a temperature sensor, a tank body, a heat insulation cover, a discharge valve and a snake-shaped electric heating wire. Active dry yeast is poured into the discharging hopper, enters the rotary joint and the round pipe through the discharging hopper, is discharged into the screening barrel through a group of through grooves, enters the tank body through the screening holes, is stirred by the mixing assembly through warm water, and simultaneously passes through the anti-caking assembly, so that the active dry yeast is discharged into the tank body through the screening holes. The group of scattering rods are used for scattering the active dry yeast which is in contact with warm water and is caked in the screening barrel, so that the agglomeration phenomenon of the active dry yeast is avoided, and the scattered active dry yeast gradually passes through the screening holes to be in contact with the warm water in the tank body, so that the active dry yeast is quickly and fully dissolved in the warm water; and the proper temperature can improve the activation degree, the activation quality and the activation efficiency of the active dry yeast.